# Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis

> **NCT05345691** · PHASE3 · COMPLETED · sponsor: **Biocon Biologics UK Ltd** · enrollment: 479 (actual)

## Conditions studied

- Postmenopausal Women With Osteoporosis

## Interventions

- **BIOLOGICAL:** Bmab 1000
- **BIOLOGICAL:** Prolia®

## Key facts

- **NCT ID:** NCT05345691
- **Lead sponsor:** Biocon Biologics UK Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-24
- **Primary completion:** 2024-06-12
- **Final completion:** 2024-06-12
- **Target enrollment:** 479 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05345691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05345691, "Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05345691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*